News headlines about Cancer Genetics (NASDAQ:CGIX) have been trending positive on Tuesday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cancer Genetics earned a daily sentiment score of 0.27 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 45.6142131522508 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Cancer Genetics (CGIX) opened at $1.82 on Tuesday. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.18. Cancer Genetics has a 52 week low of $1.55 and a 52 week high of $5.30.
Several research analysts have recently commented on CGIX shares. HC Wainwright set a $6.00 price objective on Cancer Genetics and gave the stock a “buy” rating in a report on Tuesday, January 16th. Maxim Group set a $6.00 price objective on Cancer Genetics and gave the stock a “buy” rating in a report on Wednesday, December 13th. Zacks Investment Research raised Cancer Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th. Finally, ValuEngine raised Cancer Genetics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $5.56.
In related news, Director John Pappajohn acquired 150,000 shares of the stock in a transaction on Friday, December 8th. The stock was purchased at an average price of $1.86 per share, for a total transaction of $279,000.00. Following the completion of the transaction, the director now owns 2,781,204 shares of the company’s stock, valued at approximately $5,173,039.44. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 21.30% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Cancer Genetics (CGIX) Getting Favorable Media Coverage, Report Shows” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/13/cancer-genetics-cgix-receives-coverage-optimism-score-of-0-27.html.
About Cancer Genetics
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.